Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients

Geßner, Christian; Kühn, Hartmut; Toepfer, Katja; Hammerschmidt, Stefan; Schauer, J.; Wirtz, Hubert

doi:10.1016/j.lungcan.2003.08.034

Cited by 90 publications

(79 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Carpagnano et al [64,65] also found differences in the presence of microsatellite instability in DNA obtained from EBC of LC patients compared to normal controls. Gessner and colleges [66] found similar results with the presence of P53 mutations in patients with NSLC compared to normal controls. Other studies have demonstrated that interleukin2, TNF alpha, leptin, and endothelin-1 are present in higher levels in the EBC from LC patient compared to normal controls.…”

Section: Exhaled Breath Condensate (Ebc)supporting

confidence: 57%

Lung Cancer Screening: Adjuncts and Alternatives to Low-Dose CT Scans

et al. 2013

View full text Add to dashboard Cite

Lung cancer (LC) is the leading cause of cancer related mortality in US. The National Lung Screening Trial has demonstrated a mortality benefit of using low-dose computed tomography (LDCT) in the screening of LC in high-risk individuals. The US Preventive Service Task Force has given screening for LC with LDCT a grade B recommendation; however, it recognizes gaps in generalizability to the population that would qualify for screening. There are a number of new tests in various stages of evaluation and development that hold promise as adjuncts or alternatives to LDCT. The following is a review of these novel diagnostic tests.

show abstract

Section: Exhaled Breath Condensate (Ebc)supporting

confidence: 57%

Lung Cancer Screening: Adjuncts and Alternatives to Low-Dose CT Scans

et al. 2013

View full text Add to dashboard Cite

show abstract

“…It has also been demonstrated that p53 mutations are present in EBC of patients with lung cancer, while no mutations were found in controls [ 175 ]. The oncogene KRAS has also been found in EBC of patients with lung cancer and interestingly levels were shown to decrease significantly following surgical tumour resection [ 176 ].…”

Section: Exhaled Breath Dnamentioning

confidence: 99%

Exhaled breath condensate: a comprehensive update

Ahmadzai

Huang²,

Hettiarachchi³

et al. 2013

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Since the late 1990s, a surge in interest in the analysis of exhaled breath condensate (EBC) resulted in the American Thoracic Society and European Respiratory Society (ATS/ERS) organising a Task Force in 2001 to develop guidelines on EBC collection and measurement of biomarkers. This Task Force published their guidelines in 2005 based on literature and expert opinions at that time, and multiple shortcomings and knowledge deficits were also identified. The clinical application of EBC collection and its biomarkers are currently still limited by several of these knowledge gaps, hence further guidelines for standardisation are required to ensure external validity. Using related articles produced since the publication of the ATS/ERS Task Force report, this paper attempts to provide a comprehensive update to the original guideline and review the methodological shortcomings identified. This review can hopefully serve as a yardstick for future studies involving this emerging clinical tool.

show abstract

“…EBC contains droplets of airway lining fluid (ALF) that are exhaled during normal tidal breathing. In addition to condensed gas-phase compounds, EBC contains non-volatile compounds that originate from ALF, including hydrogen peroxide, nitrite and nitrate, as well as larger molecules such as eicosanoids, proteins, and even nucleic acids [3][4][5] . The ability to non-invasively characterize airway tissue by repeated measurements of biomarkers in EBC would be invaluable for studying the time-course of dynamic inflammatory pathways that are involved in asthma exacerbation.…”

Section: Introductionmentioning

confidence: 99%

Toward point-of-care management of chronic respiratory conditions: Electrochemical sensing of nitrite content in exhaled breath condensate using reduced graphene oxide

et al. 2017

View full text Add to dashboard Cite

We present a portable non-invasive approach for measuring indicators of inflammation and oxidative stress in the respiratory tract by quantifying a biomarker in exhaled breath condensate (EBC). We discuss the fabrication and characterization of a miniaturized electrochemical sensor for detecting nitrite content in EBC using reduced graphene oxide. The nitrite content in EBC has been demonstrated to be a promising biomarker of inflammation in the respiratory tract, particularly in asthma. We utilized the unique properties of reduced graphene oxide (rGO); specifically, the material is resilient to corrosion while exhibiting rapid electron transfer with electrolytes, thus allowing for highly sensitive electrochemical detection with minimal fouling. Our rGO sensor was housed in an electrochemical cell fabricated from polydimethyl siloxane (PDMS), which was necessary to analyze small EBC sample volumes. The sensor is capable of detecting nitrite at a low over-potential of 0.7 V with respect to an Ag/AgCl reference electrode. We characterized the performance of the sensors using standard nitrite/buffer solutions, nitrite spiked into EBC, and clinical EBC samples. The sensor demonstrated a sensitivity of 0.21 μA μM − 1 cm − 2 in the range of 20-100 μM and of 0.1 μA μM − 1 cm − 2 in the range of 100-1000 μM nitrite concentration and exhibited a low detection limit of 830 nM in the EBC matrix. To benchmark our platform, we tested our sensors using seven pre-characterized clinical EBC samples with concentrations ranging between 0.14 and 6.5 μM. This enzyme-free and label-free method of detecting biomarkers in EBC can pave the way for the development of portable breath analyzers for diagnosing and managing changes in respiratory inflammation and disease.

show abstract

Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients

Cited by 90 publications

References 22 publications

Lung Cancer Screening: Adjuncts and Alternatives to Low-Dose CT Scans

Lung Cancer Screening: Adjuncts and Alternatives to Low-Dose CT Scans

Exhaled breath condensate: a comprehensive update

Toward point-of-care management of chronic respiratory conditions: Electrochemical sensing of nitrite content in exhaled breath condensate using reduced graphene oxide

Contact Info

Product

Resources

About